Desferal (desferrioxamine)--a novel activator of connective tissue-type mast cells

J Allergy Clin Immunol. 1991 Dec;88(6):854-60. doi: 10.1016/0091-6749(91)90241-f.

Abstract

The effect of Desferal (desferrioxamine), an iron-chelating agent with allergic side effects, was examined on human basophils and rodent mast cells (MCs) in vitro and in the human skin. Even at a high concentration (100 mg/ml), the drug neither induced histamine release (HR) from human basophils nor primed these cells to release higher amounts of histamine when they were activated with f-met-peptide or anti-IgE antibodies. In contrast, in all seven subjects studied, intradermal injection of Desferal (0.1 mg/ml to 100 mg/ml) elicited classic wheal-and-flare responses. Ingestion of 10 mg of cetirizine, an H1 antagonist, 3 hours before the intracutaneous administration of Desferal, significantly reduced the diameters of both wheal-and-flare reactions, indicating that the drug caused local HR. Desferal also induced HR from rat peritoneal MCs in vitro but had no effect on mouse bone marrow-derived MCs. These results suggest that Desferal has a direct, IgE-independent, stimulatory effect on connective tissue-type MCs. Thus, it may be used as a positive control in skin testing.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Basophils / drug effects
  • Basophils / immunology
  • Bone Marrow Cells
  • Connective Tissue / drug effects*
  • Connective Tissue Cells
  • Deferoxamine / pharmacology*
  • Dose-Response Relationship, Drug
  • Female
  • Histamine Release / drug effects
  • Humans
  • Male
  • Mast Cells / drug effects*
  • Mast Cells / immunology
  • Mice
  • Peritoneal Cavity / cytology
  • Rats
  • Skin / cytology
  • Skin / drug effects
  • Skin Tests

Substances

  • Deferoxamine